NAS:BLFS Key Ratios
| Market Cap $ M | 1,737.65 |
| Enterprise Value $ M | 1,670.98 |
| P/E(ttm) | 30.63 |
| PE Ratio without NRI | 36.26 |
| Forward PE Ratio | 105.43 |
| Price/Book | 4.14 |
| Price/Sales | 17.13 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 102.00 |
| EPS (TTM) $ | 1.16 |
| Beneish M-Score | -1.65 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 560.54 |
| EV-to-EBITDA | 260.68 |
| PEG | -- |
| Shares Outstanding M | 48.91 |
| Net Margin (%) | 56.39 |
| Operating Margin % | 2.90 |
| Pre-tax Margin (%) | 7.85 |
| Quick Ratio | 7.14 |
| Current Ratio | 9.69 |
| ROA % (ttm) | 14.26 |
| ROE % (ttm) | 15.54 |
| ROIC % (ttm) | 0.95 |
| Dividend Yield % | -- |
| Altman Z-Score | 37.62 |
BLFS Number of Guru Trades
BLFS Volume of Guru Trades
Gurus Latest Trades with NAS:BLFS
NAS:BLFS is held by these investors
BioLife Solutions Inc Insider Transactions
Guru Commentaries on NAS:BLFS
We added BioLife Solutions (BLFS) back into the portfolio as the company has undergone a significant transformation under current CEO Roderick de Greef. The previous acquisition strategy diluted the company's core strengths, but the focus on high-quality products has resulted in a cleaner business model. BioLife's cornerstone product, biopreservation media, is experiencing high growth rates and exceptional margins, particularly in the manufacturing of cell-based therapies, which is expected to grow over 20% annually over the next five years. Given the recent underperformance of healthcare stocks, we see a compelling long opportunity with 20%-plus top-line growth and meaningful margin expansion driving rapid EBITDA growth.
News about NAS:BLFS
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
